How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
- PMID: 22736093
- DOI: 10.1136/annrheumdis-2012-201334
How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease which is associated with an increased cardiovascular (CV) burden. Whether the risk is already present at the time of RA diagnosis remains a key area of debate. The aim of this review was to evaluate the existence of both subclinical CV changes, including endothelial dysfunction and atherosclerosis, CV risk factors, as well as CV disease manifestations such as coronary heart disease, myocardial infarction, congestive heart failure and CV death prior to RA diagnosis and during the first few years of the disease. The state of the endothelial function remains controversial in patients with newly diagnosed RA. Studies with impaired brachial artery vasodilatory responses at baseline showed a reversal of the dysfunction after 6-12 months of anti-inflammatory therapy. Morphological evidence of arterial wall atherosclerosis, measured by carotid artery intima-media thickness or the prevalence of carotid plaques, was already present during the first year following RA diagnosis. The risk of coronary heart disease and myocardial infarction is increased even prior to and, at the latest, within 1 year of the clinical onset of RA. The prevalence of hypertension was similar among patients with RA and controls. CV mortality may not increase within the first years of RA diagnosis. In conclusion, the CV risk seems to increase sooner after the RA diagnosis than previously thought. In addition to systematic CV risk assessment, patients with early RA might benefit from being targeted with stricter than conventional CV risk prevention and intervention.
Similar articles
-
Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation.Atherosclerosis. 2018 Apr;271:214-222. doi: 10.1016/j.atherosclerosis.2018.03.004. Epub 2018 Mar 2. Atherosclerosis. 2018. PMID: 29524864
-
SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.PLoS One. 2013 Oct 21;8(10):e77695. doi: 10.1371/journal.pone.0077695. eCollection 2013. PLoS One. 2013. PMID: 24204921 Free PMC article.
-
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis.Clin Rheumatol. 2025 Apr;44(4):1485-1492. doi: 10.1007/s10067-025-07364-5. Epub 2025 Feb 17. Clin Rheumatol. 2025. PMID: 39962010 Free PMC article.
-
Cardiovascular morbidity and mortality in rheumatoid arthritis.Am J Med. 2008 Oct;121(10 Suppl 1):S9-14. doi: 10.1016/j.amjmed.2008.06.011. Am J Med. 2008. PMID: 18926169 Free PMC article. Review.
-
Cardiovascular disease in rheumatoid arthritis.Biomed Pharmacother. 2006 Dec;60(10):673-7. doi: 10.1016/j.biopha.2006.09.006. Epub 2006 Oct 10. Biomed Pharmacother. 2006. PMID: 17049201 Review.
Cited by
-
Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.Heart Fail Clin. 2014 Apr;10(2):339-52. doi: 10.1016/j.hfc.2013.10.003. Epub 2014 Jan 10. Heart Fail Clin. 2014. PMID: 24656110 Free PMC article. Review.
-
Association of congestive heart failure with mortality in individuals with rheumatoid arthritis: a cohort study.Clin Rheumatol. 2024 Apr;43(4):1287-1297. doi: 10.1007/s10067-024-06878-8. Epub 2024 Feb 20. Clin Rheumatol. 2024. PMID: 38378912
-
Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activity.BMC Rheumatol. 2023 Dec 1;7(1):43. doi: 10.1186/s41927-023-00367-2. BMC Rheumatol. 2023. PMID: 38037148 Free PMC article.
-
Co-morbidity in patients with early rheumatoid arthritis - inflammation matters.Arthritis Res Ther. 2016 Jan 28;18:33. doi: 10.1186/s13075-016-0928-y. Arthritis Res Ther. 2016. PMID: 26818851 Free PMC article.
-
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial.RMD Open. 2021 Mar;7(1):e001591. doi: 10.1136/rmdopen-2021-001591. RMD Open. 2021. PMID: 33685928 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical